Asenapine

CHEMBL3187365 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

285.8 g/mol

LogP

3.8

Phase

4

An atypical antipsychotic that blocks multiple dopamine and serotonin receptor subtypes in the brain to reduce psychotic symptoms and mood instability in schizophrenia and bipolar disorder. The sublingual formulation is absorbed through the mouth lining to bypass first-pass metabolism.

Peso Molecular

285,8000 g/mol

LogP

3,80

TPSA

12,50 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Schizophrenia Bipolar Disorder Gastroesophageal Reflux Disease Stroke Major Depressive Disorder

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1

InChI

InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3

Molecular Formula

C17H16ClNO

HBD / HBA

- / 2

Ligações Rotacionáveis

0

Átomos Pesados

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An atypical antipsychotic that blocks multiple dopamine and serotonin receptor subtypes in the brain to reduce psychotic symptoms and mood instability in schizophrenia and bipolar disorder. The sublingual formulation is absorbed through the mouth lining to bypass first-pass metabolism.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Asenapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3187365. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 163091. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Asenapine no PillFYI

Estrutura

Dados Rápidos

Fórmula: C17H16ClNO
Sinônimos: 2

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.